0000899243-22-037521.txt : 20221202 0000899243-22-037521.hdr.sgml : 20221202 20221202192140 ACCESSION NUMBER: 0000899243-22-037521 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221202 FILED AS OF DATE: 20221202 DATE AS OF CHANGE: 20221202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sorrento Therapeutics, Inc. CENTRAL INDEX KEY: 0000850261 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39852 FILM NUMBER: 221443418 BUSINESS ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-203-4100 MAIL ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: QUIKBYTE SOFTWARE INC DATE OF NAME CHANGE: 19920703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Scilex Holding Co CENTRAL INDEX KEY: 0001820190 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: (650) 516-4310 MAIL ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: Scilex Holding Company/DE DATE OF NAME CHANGE: 20221117 FORMER COMPANY: FORMER CONFORMED NAME: Vickers Vantage Corp. I DATE OF NAME CHANGE: 20200804 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-02 0 0001820190 Scilex Holding Co SCLX 0000850261 Sorrento Therapeutics, Inc. 4955 DIRECTORS PLACE SAN DIEGO CA 94303 0 0 1 0 Warrants to Purchase Common Stock 11.50 2022-12-02 4 P 0 224841 0.3507 A 2022-11-10 2027-11-10 Common Stock 224841 4490617 D The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.32 to $0.36 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price. /s/ Henry Ji, Ph.D., President, Chief Executive Officer and Chairman of the Board, Sorrento Therapeutics, Inc. 2022-12-02